Sign in to view content

Assessing Commercially Available Cell Therapies for Retinal Disease in the U.S.

Ajay E Kuriyan, MD, MS
Daniel Simhaee, MD

Video
Published 2018

Related

Pradeepa Yoganathan Last Word
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Annual Meeting Talks
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Phase 2 Trial of Ciliary Neurotrophic Factor for Macular Telangiectasia
Updates from the Field
2017

Category: Hereditary Retinal Disease & Genetics

See more